cardioКардиологияKardiologiia0022-90402412-5660Kardiomag10.18087/cardio.2477cardio-242Research ArticleСЛУЧАЙ ИЗ ПРАКТИКИОпыт госпитальной инициации сакубитрил/валсартана у пациентки после эпизода декомпенсации сердечной недостаточностиExperience of hospital initiation of sacubitril/valsartan in a female patient after acute decompensated heart failureГалочкинС. А.GalochkinS. A.noemail@neicon.ruЛукинаО. И.LukinaO. I.noemail@neicon.ruМерайИ. А.MerayI. A.noemail@neicon.ruВиллевальдеС. В.VillevaldeS. V.noemail@neicon.ruКобалаваЖ. Д.KobalavaZh. D.noemail@neicon.ruФГАОУ ВО «РУДН»РоссияPeoples’ Friendship University of RussiaRussian Federation201818112018585S6064Copyright © Kardiomag, 20182018KardiomagKardiomaghttps://cardio.elpub.ru/jour/about/submissions#copyrightNoticehttps://cardio.elpub.ru/jour/article/view/242

В статье обсуждается ведение пациентки с ХСН с низкой ФВ ЛЖ после эпизода острой декомпенсации. Включение 1-го представителя нового класса ангиотензиновых рецепторов и неприлизина ингибитора сакубитрил/валсартана в состав комплексной терапии вместо ингибиторов ангиотензин-превращающего фермента позволило быстро добиться состояния компенсации и поддерживать его. Лечение хорошо переносилось и не сопровождалось клинически значимыми нежелательными явлениями.

Le article discusses management of a female patient with chronic heart failure with reduced left ventricular ejection fraction after an episode of acute decompensation. Replacing an angiotensin-converting enzyme inhibitor with a representative of a new angiotensin receptor-neprilysin inhibitor class, sacubitril/valsartan, in the combination therapy allowed fast achievement and maintenance of the compensation state. RAe treatment was well tolerated and was not associated with clinically significant adverse effects.

хроническая сердечная недостаточность со сниженной фракцией выброса левого желудочкаострая декомпенсация хронической сердечной недостаточностиангиотензиновых рецепторов и неприлизина ингибиторсакубитрил/валсартанHFrEFacute decompensation of chronic heart failureangiotensin receptor-neprilysin inhibitorsacubitril/valsartanReferencesMosterd A., Hoes A.W. Clinical epidemiology of heart failure. Heart. 2007,93 (9):1137-46. DOI:10.1136/hrt. 2003.025270Mosterd A., Hoes A.W. Clinical epidemiology of heart failure. Heart. 2007,93 (9):1137-46. DOI:10.1136/hrt. 2003.025270Dunlay SM, Roger V.L. Understanding the Epidemic of Heart Failure: Past, Present, and Future. Current Heart Failure Reports. 2014,11 (4):404-15. DOI:10.1007/s11897-014-0220-xDunlay SM, Roger V.L. Understanding the Epidemic of Heart Failure: Past, Present, and Future. Current Heart Failure Reports. 2014,11 (4):404-15. DOI:10.1007/s11897-014-0220-xМареев В. Ю., Фомин И. В., Агеев Ф. Т., Арутюнов Г. П., Беграмбекова Ю. Л., Васюк Ю. А. и др. Хроническая СН (ХСН). Журнал Сердечная Недостаточность. 2017,18 (1):3-40. DOI:10.18087/rhfj. 2017.1.2346Мареев В. Ю., Фомин И. В., Агеев Ф. Т., Арутюнов Г. П., Беграмбекова Ю. Л., Васюк Ю. А. и др. Хроническая СН (ХСН). Журнал Сердечная Недостаточность. 2017,18 (1):3-40. DOI:10.18087/rhfj. 2017.1.2346Ponikowski P., Voors AA, Anker SD, Bueno H., Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016,37 (27):2129-200. DOI:10.1093/eurheartj/ehw128Ponikowski P., Voors AA, Anker SD, Bueno H., Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016,37 (27):2129-200. DOI:10.1093/eurheartj/ehw128Yancy CW, Jessup M., Bozkurt B., Butler J., Casey DE, Colvin MM et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society ofAmerica. Circulation. 2017,136 (6):e137-61. DOI:10.1161/CIR. 0000000000000509Yancy CW, Jessup M., Bozkurt B., Butler J., Casey DE, Colvin MM et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society ofAmerica. Circulation. 2017,136 (6):e137-61. DOI:10.1161/CIR. 0000000000000509Hubers SA, Brown N.J. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition. Circulation. 2016,133 (11):1115-24. DOI:10.1161/CIRCULATIONAHA. 115.018622Hubers SA, Brown N.J. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition. Circulation. 2016,133 (11):1115-24. DOI:10.1161/CIRCULATIONAHA. 115.018622McMurray JJV, Packer M., Desai AS, Gong J., Lefkowitz MP, Rizkala AR et al. Angiotensin - niprilysin Inhibition versus enalapril in heart failure. New EnglandJournal of Medicine. 2014,371 (11):993-1004. DOI:10.1056/NEJMoa1409077McMurray JJV, Packer M., Desai AS, Gong J., Lefkowitz MP, Rizkala AR et al. Angiotensin - niprilysin Inhibition versus enalapril in heart failure. New EnglandJournal of Medicine. 2014,371 (11):993-1004. DOI:10.1056/NEJMoa1409077Jhund PS, Fu M., Bayram E., Chen C-H, Negrusz-Kawecka M., Rosenthal A. et al. Efficacy and safety of LCZ696 (sacubitril-valsartan) ac cording to age: insights from PARADIGM-HF. European Heart Journal. 2015,36 (38):2576-84. DOI:10.1093/eurheartj/ehv330Jhund PS, Fu M., Bayram E., Chen C-H, Negrusz-Kawecka M., Rosenthal A. et al. Efficacy and safety of LCZ696 (sacubitril-valsartan) ac cording to age: insights from PARADIGM-HF. European Heart Journal. 2015,36 (38):2576-84. DOI:10.1093/eurheartj/ehv330Solomon SD, Claggett B., Desai AS, Packer M., Zile M., Swedberg K. et al. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection FractionCLINICAL PERSPECTIVE: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Circulation: Heart Failure. 2016,9 (3):e002744. DOI:10.1161/CIRCHEART-FAILURE. 115.002744Solomon SD, Claggett B., Desai AS, Packer M., Zile M., Swedberg K. et al. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection FractionCLINICAL PERSPECTIVE: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Circulation: Heart Failure. 2016,9 (3):e002744. DOI:10.1161/CIRCHEART-FAILURE. 115.002744Kristensen SL, Preiss D., Jhund PS, Squire I., Cardoso JS, Merkely B. et al. Risk Related to Pre - Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction CLINICAL PERSPECTIVE: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circulation: Heart Failure. 2016,9 (1):e002560. DOI:10.1161/ CIRCHEARTFAILURE. 115.002560Kristensen SL, Preiss D., Jhund PS, Squire I., Cardoso JS, Merkely B. et al. Risk Related to Pre - Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction CLINICAL PERSPECTIVE: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circulation: Heart Failure. 2016,9 (1):e002560. DOI:10.1161/ CIRCHEARTFAILURE. 115.002560Böhm M., Young R., Jhund PS, Solomon SD, Gong J., Lefkowitz MP et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J. 2017,38 (15):1132-43. DOI:10.1093/eur-heartj/ehw570Böhm M., Young R., Jhund PS, Solomon SD, Gong J., Lefkowitz MP et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J. 2017,38 (15):1132-43. DOI:10.1093/eur-heartj/ehw570Mogensen U. Sunday 28 August 2016. European Heart Journal. 2016,37 (suppl 1 ): 193. DOI:10.1093/eurheartj/ehw432Mogensen U. Sunday 28 August 2016. European Heart Journal. 2016,37 (suppl 1 ): 193. DOI:10.1093/eurheartj/ehw432Damman K. Monday, 31 August 2015. European Heart Journal. 2015,36 (suppl 1):509-847. DOI:10.1093/eurheartj/ehv400Damman K. Monday, 31 August 2015. European Heart Journal. 2015,36 (suppl 1):509-847. DOI:10.1093/eurheartj/ehv400Desai AS, McMurray JJV Packer M., Swedberg K., Rouleau JL, Chen F. et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. European Heart Journal. 2015,36(30):1990-7. DOI:10.1093/eurheartj/ehv186Desai AS, McMurray JJV Packer M., Swedberg K., Rouleau JL, Chen F. et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. European Heart Journal. 2015,36(30):1990-7. DOI:10.1093/eurheartj/ehv186

The authors declare that there are no conflicts of interest present.